Cabazitaxel + carboplatin in treatment of mCRPC

A newly published article in Lancet Oncology has suggested that “taxane–platinum combinations have a clinically beneficial role in advanced prostate cancer”. … READ MORE …

Statins and the treatment of mCRPC with chemotherapy

A report on the UroToday web site has addressed a presentation given this week at the ESMO 2018 Congress in Munich, Germany, that is relevant to the potential value of taking a statin while you are being treated for very late stage prostate cancer. … READ MORE …

FDA approves lower dose of cabazitaxel in treatment of mCRPC

Yesterday, in line with previously reported data, the US Food and Drug Administration (FDA) approved the used of a 20 mg/ml dose of cabazitaxel (Jevtana) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Patient preference and type of chemotherapy for mCRPC

In another presentation from the ESMO meeting in  Madrid, Spain, Fizazi et al. presented data from the randomized CABA-DOC trial  exploring patients’ preferences for either docetaxel or cabazitaxel as a first-line form of chemotherapy. … READ MORE …

Differing chemotherapies and their effects in the treatment of mCRPC

The results of two recent, large clinical trials may have some impact on the clinical use of cabazitaxel (Jevtana) in the treatment of late-stage prostate cancer. … READ MORE …

Final data from the failed, Phase III, AFFINITY trial of curstirsen + cabazitaxel + prednisone

In August we had reported on an announcement by OncoGenex Pharmaceuticals that, in the Phase III AFFINITY trial, the combination of custirsen + cabazitaxel (Jevtana) + prednisone had no significant impact on overall survival of men with metastatic, castration-resistant prostate cancer (mCRPC) who had already received first-line chemotherapy by comparison with cabazitaxel + prednisone alone. … READ MORE …

NICE changes it’s tune about cabazitaxel

According to news reports this morning, the National Institute for Health and Care Excellence (NICE) in England has changed its tune about covering cabazitaxel (Jevtana) as a treatment for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ NORE …